An interventional study of Visceral Manifold and Thoracic Bifurcation and Unitary Manifold in Thoracoabdominal Aneurysms, sponsored by Sanford Health. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-16.
Sponsored by Sanford Health · Not applicable, Interventional, and Treatment
The primary objective of the Visceral Manifold and Unitary Device Study is to assess the use of the thoracic bifurcation and the visceral manifold or the unitary device to repair thoracoabdominal aortic aneurysms in patients having appropriate anatomy. The primary intent of the study is to assess safety and preliminary effectiveness of the device. Additionally, the study will assess technical success and treatment success at each follow-up interval.
The primary objective of the clinical investigation Visceral Manifold and Unitary Device Study is to assess the use of the thoracic bifurcation and the visceral manifold or the unitary stent graft system to repair thoracoabdominal aortic aneurysms in patients having appropriate anatomy. The primary intent of the study is to assess safety (i.e. freedom from major adverse events (MAE) at 30 days) and preliminary effectiveness (i.e., treatment success and technical success) of the device (i.e., the proportion of treatment group subjects that achieve and maintain treatment success at one year). Additionally, the study will assess technical success and treatment success at each follow-up interval.
960 studies on the registry are indexed under Aneurysm; 175 are open to participants now.
This study's planned enrollment of 250 is above the median of 72 across 462 interventional studies indexed under Aneurysm.
Browse Aneurysm studies →Sanford Health is the lead sponsor of 39 studies on the registry; 8 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Proximal landing zone for the thoracic bifurcation stent graft:
•≥ 2.5 cm of nonaneurysmal aortic segment including previously placed graft material (neck) distal to the left subclavian artery (LSA)
Proximal landing zone for the unitary manifold stent graft:
Exclusion Criteria:
General exclusion
Medical exclusion criteria
Anatomical exclusion criteria
Expanded Selection Arm Inclusion Criteria
Patient that meets the criteria for inclusion in the primary study arm but has one or more of the following criteria which would exclude them from the primary study arm:
OR
Patient that meets criteria for inclusion in the primary study arm and:
The TAAA Debranching Stent Graft System is comprised of two investigational devices including the Thoracic Bifurcation and the Visceral Manifold and the Unitary Manifold. The thoracic bifurcation and the visceral manifold as well as the unitary manifold work to facilitate endovascular stenting of the visceral vessels (renals, celiac, SMA) while maintaining flow to the visceral and infrarenal segments.
Device: Visceral Manifold and Thoracic Bifurcation · Device: Unitary Manifold
The expanded selection arm is for subjects not eligible for open repair or other endovascular options due to comorbidities or anatomical limitations and do not meet inclusion in the primary study arm. The Thoracic Bifurcation and the Visceral Manifold as well as the Unitary Manifold work to facilitate endovascular stenting of the visceral vessels (renals, celiac, SMA) while maintaining flow to the visceral and infrarenal segments.
Device: Visceral Manifold and Thoracic Bifurcation · Device: Unitary Manifold
Visceral Manifold and Thoracic Bifurcation Endovascular stent graft system
Unitary Manifold Endovascular stent graft system
Freedom from major adverse events (MAEs) at 30 days
Major adverse events include death, bowel ischemia, myocardial infarction, paraplegia, renal failure, respiratory failure, and stroke.
Time frame: 30 days
Treatment success and technical success at 1 year
Treatment success is defined as a composite of technical success and freedom from the following: * Aneurysm enlargement * Aneurysm rupture * Aneurysm-related mortality * Conversion to open repair * Secondary intervention for migration, Type I and III endoleaks, device integrity failure , and patency-related events
Time frame: 1 year
Treatment success at various timepoints
Treatment success and the individual components of treatment success including freedom from the following: * Aneurysm enlargement * Aneurysm-related mortality * Aneurysm rupture * Conversion to open repair * Secondary intervention for migration, type I and III endoleaks, device integrity failure, and patency-related events. * Renal failure * All-cause mortality * Endoleaks * Device integrity failure * Patency-related events * Other device-related events
Time frame: 1 month, 6 months, 1 year, 2 years, 3 years, 4 years, 5 years
Plan to share: No
This study is active, not recruiting, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Sanford Health